Successive cycles of anti-CEA × anti-HSG bsAb and lutetium-177-labeled hapten based PRIT also effectively delayed the growth of human CRC tumors and enhanced survival from 13 to 65 days for mice treated with three cycles vs. one cycle of PRIT [55]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.